Table 1 Baseline characteristics of included trials
First author | Publication years | Country | Number (n) | CRT | Age Median (range) | TILs subsets | Sample time | TILs site | Method | curative resection | Outcome measured | Follow up Median (range)(M) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ladoire S et al.[26] | 2011 | France | 162 | YES/YES | NR | FOXP3+/CD8+ | B-NC/post | Peritumoral | IHC | YES | RFS; OS | NR |
Lee S et al. [30] | 2013 | Korea | 86 | NR/YES | NR | FOXP3+ | NR | Peritumoral | IHC | NR | RFS;OS | 73.5(24.2–120.0) |
Mahmoud SMA et al. [27] | 2011 | United Kingdom | 1445 | NR/YES | NR | FOXP3+ | Post | Intratumoural;distant stromal; peritumoral | IHC/TMA | YES | OS;RFS | 128(4–243) |
Liu F et al. [7] | 2011 | China | 1270 | NO/YES | 52(19–92) | FOXP3+/CD8+ | Post | Intratumoural; peritumoral | IHC | YES | OS; RFS | 66(1–78) |
West NR et al. [32] | 2013 | Canada | 175 | NR | NR | FOXP3+/CD8+ | Post | Total | IHC | YES | RFS; OS | 83 |
Bates GJ et al. [23] | 2006 | United Kingdom | 299 | NR/YES | NR | FOXP3+ | Post | Total | IHC | YES | RFS; OS | 87.6(2.4–135.6) |
Takenaka M et al. [31] | 2013 | Japan | 100 | NO/NR | NR | FOXP3+ | Post | Total | IHC | YES | OS; RFS | NR |
Maeda N et al. [35] | 2014 | Japan | 90 | NO/YES | NR | FOXP3+ | Post | Total | IHC | YES | OS; RFS | 67(7.8–90.5) |
Sun S et al. [36] | 2014 | China | 208 | NO/YES | 57.6(31–85) | FOXP3+/CD8+/PD-1 | Post | Intratumoural; peritumoral | IHC | YES | OS; RFS | 72(8.04–102.24) |
Aruga T et al. [24] | 2009 | Japan | 87 | YES/NR | 51(23–69) | FOXP3+ | B-NC | Total | IHC | NR | OS; RFS | 46.3(5.3–89.1) |
De Kruijf EM et al. [25] | 2010 | Netherlands | 556 | NO/YES | 57(23–96) | HCA2/HC10/Foxp3+ | Post | Intratumoural | IHC | YES | OS; RFS | 228(0–276) |
Liu F et al. [28] | 2012 | China | 132 | YES/YES | 53(38–72) | FOXP3+ | B-NC/post | Intratumoural; peritumoral | IHC | YES | pCR; OS; RFS | 62(18–73) |
Liu S et al. [34] | 2014 | Canada | 3277 | NR/YES | 58.9(23–95) | FOXP3+/CD8+ | Post | Intratumoural | IHC/TMA | NR | OS; RFS | 151(1.2–222) |
Kim ST et al. [29] | 2013 | Korea | 72 | YES/NR | 49(16–83) | FOXP3+/CD8+/CD4+ | B-NC/post | Total | IHC | YES | RFS | 34(21.9–38.3) |
Tsang JY et al. [37] | 2014 | China | 84 | NO/NR | 56.3(44.4–68.2) | FOXP3+/CD8+ | Post | Intratumoural; peritumoral | IHC/TMA | YES | NO | NR |
Kim S et al. [33] | 2014 | Korea | 143 | NO/NR | NR | FOXP3+/CD8+/CD4+ | Post | Intratumoural; peritumoral | IHC | YES | OS; RFS | 69 |
Seo AN et al. [38] | 2013 | Korea | 153 | YES/NR | NR | FOXP3+/CD8+/CD4+ | B-NC/post | Intratumoural | IHC | YES | pCR; | NR |